Truong Robinson, Tang Vincent, Grennan Troy, Tan Darrell H S
Faculty of Medicine, University of Toronto, 1 King's College Cir, Toronto, ON M5S 1A8, Canada.
Centre for Urban Health Solutions, St. Michael's Hospital, 209 Victoria St, Toronto, ON M5B 1T8, Canada.
JAC Antimicrob Resist. 2022 Feb 15;4(1):dlac009. doi: 10.1093/jacamr/dlac009. eCollection 2022 Mar.
There is interest in doxycycline as prophylaxis against sexually transmitted infections (STIs), but concern about antimicrobial resistance (AMR). We conducted a systematic review (CRD42021273301) of the impact of oral tetracycline-class antibiotics on AMR in normal flora.
We searched MEDLINE, EMBASE, the Cochrane Library (1940-2021) and conference proceedings (2014-21) for randomized controlled trials in adults comparing daily oral tetracycline-class antibiotics to non-tetracycline controls. The primary outcome was AMR to tetracyclines; secondary outcomes included resistance to non-tetracyclines. Data were inappropriate for meta-analysis, so we analysed findings descriptively.
Our search yielded 6265 abstracts of which 7 articles fulfilled inclusion criteria. Most were at moderate/high risk of bias, generally due to inadequate methodologic reporting. Studies used doxycycline, tetracycline, oxytetracycline or minocycline for 2-18 weeks. Most observed an increased burden of tetracycline resistance, including in subgingival (= 3 studies), gastrointestinal (= 2) and upper respiratory tract (= 1) flora; one study of skin flora found no change in tetracycline-resistant species after 18 weeks of oxytetracycline/minocycline. Four studies reassessed AMR at 2-50 weeks post-intervention and reported varying degrees of resistance. Three articles reported on the prevalence of non-tetracycline AMR after doxycycline prophylaxis, of which one found a transient increase among gastrointestinal ; the other two showed no difference from control.
Although the effects are modest and transient, limited data from small prospective studies may suggest that oral tetracyclines for 2-18 weeks increase resistance in subgingival, gastrointestinal and upper respiratory tract flora. STI prophylaxis trials should include AMR in commensal bacteria as study outcomes.
人们对强力霉素作为预防性传播感染(STIs)的药物感兴趣,但担心其会导致抗菌药物耐药性(AMR)。我们对口服四环素类抗生素对正常菌群中AMR的影响进行了一项系统综述(CRD42021273301)。
我们检索了MEDLINE、EMBASE、Cochrane图书馆(1940 - 2021年)和会议论文集(2014 - 2021年),以查找比较每日口服四环素类抗生素与非四环素类对照的成人随机对照试验。主要结局是对四环素的AMR;次要结局包括对非四环素类药物的耐药性。数据不适合进行荟萃分析,因此我们对研究结果进行了描述性分析。
我们的检索共得到6265篇摘要,其中7篇文章符合纳入标准。大多数研究存在中度/高度偏倚风险,通常是由于方法学报告不充分。研究使用强力霉素、四环素、土霉素或米诺环素治疗2 - 18周。大多数研究观察到四环素耐药负担增加,包括龈下菌群(3项研究)、胃肠道菌群(2项研究)和上呼吸道菌群(1项研究);一项关于皮肤菌群的研究发现,在使用土霉素/米诺环素18周后,四环素耐药菌种类没有变化。四项研究在干预后2 - 50周重新评估了AMR,并报告了不同程度的耐药情况。三篇文章报告了强力霉素预防后非四环素类AMR的流行情况,其中一篇发现胃肠道菌群中有短暂增加;另外两篇与对照组无差异。
尽管影响较小且短暂,但来自小型前瞻性研究的有限数据可能表明,口服四环素类药物2 - 18周会增加龈下、胃肠道和上呼吸道菌群的耐药性。性传播感染预防试验应将共生细菌中的AMR作为研究结局。